Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Treating myeloma cast nephropathy without treating myeloma
Nelson Leung
Nelson Leung
Published April 9, 2012
Citation Information: J Clin Invest. 2012;122(5):1605-1608. https://doi.org/10.1172/JCI63248.
View: Text | PDF
Commentary

Treating myeloma cast nephropathy without treating myeloma

  • Text
  • PDF
Abstract

Cast nephropathy is the result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein (THP). It is a hallmark of multiple myeloma that has significant consequences. Treatment strategies in the past focused on reduction of serum FLC by control of the myeloma. In this issue, Ying et al. report on their successful synthesis of a cyclized competitor peptide that blocks the binding of FLC to THP. In animal studies, this cyclized peptide was capable of reducing cast formation and kidney injury, representing a novel treatment strategy for cast nephropathy that does not depend on the responsiveness of the myeloma to chemotherapy.

Authors

Nelson Leung

×

Figure 1

Light microscopy of a kidney with cast nephropathy stained with PAS stain.

Options: View larger image (or click on image) Download as PowerPoint
Light microscopy of a kidney with cast nephropathy stained with PAS stai...
Multiple distal tubules are filled with PAS-negative casts (asterisks). Some of the cast have a fractured appearance. An inflammatory cellular reaction is seen surrounding the casts (single-headed arrows). Inflammatory infiltrates (single-headed arrows) are seen in the interstitium of the kidney, usually near obstructed tubules. All of these are characteristic features of cast nephropathy. Increased spacing (double-headed arrows) between tubules throughout the biopsy indicates either edema (acute) or tubular atrophy (chronic) and is the result of the injury from the casts. Normally tubules should be lined back to back with each other.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts